*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter - as a primary diagnosis code | T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 5.36 | |
| Readmission Rate (%) | 19.71 | |
| Unplanned Readmission Rate (%) | NA | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 918: POISONING AND TOXIC EFFECTS OF DRUGS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|
| Total Hospitalizations at DRG | 71,748 |
| Total Hospitalizations with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 19 |
| DRG Share of Total Hospitalizations | 0.22 |
| % of Total ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter in DRG | 67.86 |
| Avg LOS at DRG | 2.93 |
| Avg LOS with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 3.0 |
| Readmission Rate at DRG | 33.86 |
| Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA |
| Unplanned Readmission Rate at DRG | 10.34 |
| Unplanned Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA |
| Total Medicare payments at DRG | $313,351,773 |
| Total Medicare payments with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $75,922 |
| Total Medicare payment per Day at DRG | $1,489 |
| Total Medicare payment per Day with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $1,332 |
| Total Medicare payment per Hospitalization at DRG | $4,367 |
| Total Medicare payment per Hospitalization with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $3,996 |
| Total Medicare Charges at DRG | $1,750,048,705 |
| Total Medicare Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $295,684 |
| Avg Charges at DRG | $24,392 |
| Avg Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $15,562 |
| Mortality Rate at DRG | 0.22 |
| Mortality Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA |
| SNF Discharge Rate at DRG | 7.61 |
| SNF Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA |
| Home Discharge Rate at DRG | 51.88 |
| Home Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 57.89 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 558: TENDONITIS, MYOSITIS AND BURSITIS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 092: OTHER DISORDERS OF NERVOUS SYSTEM WITH COMPLICATION OR COMORBIDITY (CC) | DRG 439: DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 39,224 | ||||
| Total Hospitalizations with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 695 | ||||
| DRG Share of Total Hospitalizations | 0.12 | ||||
| % of Total ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter in DRG | 7.49 | ||||
| Avg LOS at DRG | 4.42 | ||||
| Avg LOS with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 4.09 | ||||
| Readmission Rate at DRG | 18.22 | ||||
| Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 16.64 | ||||
| Unplanned Readmission Rate at DRG | 9.29 | ||||
| Unplanned Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 8.62 | ||||
| Total Medicare payments at DRG | $239,468,231 | ||||
| Total Medicare payments with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $3,756,952 | ||||
| Total Medicare payment per Day at DRG | $1,381 | ||||
| Total Medicare payment per Day with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $1,323 | ||||
| Total Medicare payment per Hospitalization at DRG | $6,105 | ||||
| Total Medicare payment per Hospitalization with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $5,406 | ||||
| Total Medicare Charges at DRG | $1,104,766,925 | ||||
| Total Medicare Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $19,641,224 | ||||
| Avg Charges at DRG | $28,166 | ||||
| Avg Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $28,261 | ||||
| Mortality Rate at DRG | 0.2 | ||||
| Mortality Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 32.92 | ||||
| SNF Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 26.33 | ||||
| Home Discharge Rate at DRG | 33.95 | ||||
| Home Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 45.61 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 557: TENDONITIS, MYOSITIS AND BURSITIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 442: DISORDERS OF LIVER EXCEPT MALIGNANCY, CIRRHOSIS OR ALCOHOLIC HEPATITIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 440: DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 14,153 | ||||
| Total Hospitalizations with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 244 | ||||
| DRG Share of Total Hospitalizations | 0.04 | ||||
| % of Total ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter in DRG | 2.63 | ||||
| Avg LOS at DRG | 7.2 | ||||
| Avg LOS with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 6.57 | ||||
| Readmission Rate at DRG | 23.16 | ||||
| Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 23.18 | ||||
| Unplanned Readmission Rate at DRG | 13.2 | ||||
| Unplanned Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 11.82 | ||||
| Total Medicare payments at DRG | $151,650,948 | ||||
| Total Medicare payments with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $2,314,098 | ||||
| Total Medicare payment per Day at DRG | $1,488 | ||||
| Total Medicare payment per Day with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $1,443 | ||||
| Total Medicare payment per Hospitalization at DRG | $10,715 | ||||
| Total Medicare payment per Hospitalization with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $9,484 | ||||
| Total Medicare Charges at DRG | $682,339,009 | ||||
| Total Medicare Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $12,981,752 | ||||
| Avg Charges at DRG | $48,212 | ||||
| Avg Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $53,204 | ||||
| Mortality Rate at DRG | 2.64 | ||||
| Mortality Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 42.61 | ||||
| SNF Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 33.61 | ||||
| Home Discharge Rate at DRG | 20.07 | ||||
| Home Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 27.87 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 247: PERCUTANEOUS CARDIOVASCULAR PROCEDURES WITH DRUG-ELUTING STENT WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 948: SIGNS AND SYMPTOMS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 065: INTRACRANIAL HEMORRHAGE OR CEREBRAL INFARCTION WITH COMPLICATION OR COMORBIDITY (CC) OR TPA IN 24 HOURS | DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 392: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 269,438 | ||||
| Total Hospitalizations with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 168 | ||||
| DRG Share of Total Hospitalizations | 0.82 | ||||
| % of Total ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter in DRG | 1.81 | ||||
| Avg LOS at DRG | 2.51 | ||||
| Avg LOS with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 2.71 | ||||
| Readmission Rate at DRG | 10.86 | ||||
| Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 9.26 | ||||
| Unplanned Readmission Rate at DRG | 8.03 | ||||
| Unplanned Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA | ||||
| Total Medicare payments at DRG | $3,352,957,239 | ||||
| Total Medicare payments with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $2,157,288 | ||||
| Total Medicare payment per Day at DRG | $4,952 | ||||
| Total Medicare payment per Day with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $4,731 | ||||
| Total Medicare payment per Hospitalization at DRG | $12,444 | ||||
| Total Medicare payment per Hospitalization with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $12,841 | ||||
| Total Medicare Charges at DRG | $22,958,558,443 | ||||
| Total Medicare Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $15,000,727 | ||||
| Avg Charges at DRG | $85,209 | ||||
| Avg Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $89,290 | ||||
| Mortality Rate at DRG | 0.31 | ||||
| Mortality Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 2.62 | ||||
| SNF Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 88.57 | ||||
| Home Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 89.88 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 091: OTHER DISORDERS OF NERVOUS SYSTEM WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 441: DISORDERS OF LIVER EXCEPT MALIGNANCY, CIRRHOSIS OR ALCOHOLIC HEPATITIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 556: SIGNS AND SYMPTOMS OF MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 690: KIDNEY AND URINARY TRACT INFECTIONS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 872: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 101,617 | ||||
| Total Hospitalizations with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 140 | ||||
| DRG Share of Total Hospitalizations | 0.31 | ||||
| % of Total ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter in DRG | 1.51 | ||||
| Avg LOS at DRG | 9.5 | ||||
| Avg LOS with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 7.4 | ||||
| Readmission Rate at DRG | 26.88 | ||||
| Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 28.57 | ||||
| Unplanned Readmission Rate at DRG | 19.26 | ||||
| Unplanned Readmission Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 16.67 | ||||
| Total Medicare payments at DRG | $1,599,186,807 | ||||
| Total Medicare payments with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $1,784,306 | ||||
| Total Medicare payment per Day at DRG | $1,656 | ||||
| Total Medicare payment per Day with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $1,722 | ||||
| Total Medicare payment per Hospitalization at DRG | $15,737 | ||||
| Total Medicare payment per Hospitalization with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $12,745 | ||||
| Total Medicare Charges at DRG | $4,836,538,333 | ||||
| Total Medicare Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $8,032,383 | ||||
| Avg Charges at DRG | $47,596 | ||||
| Avg Charges with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | $57,374 | ||||
| Mortality Rate at DRG | 2.8 | ||||
| Mortality Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 20.21 | ||||
| SNF Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 37.86 | ||||
| Home Discharge Rate at DRG | 20.17 | ||||
| Home Discharge Rate with ICD T466X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter | 17.14 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| CHRISTIANA CARE WILMINGTON HOSPITAL | 501 W 14TH ST | WILMINGTON | DE | 19801 | 41 |
| SHARP GROSSMONT HOSPITAL | 5555 GROSSMONT CENTER DR | LA MESA | CA | 91942 | 35 |
| CENTRA VIRGINIA BAPTIST HOSPITAL | 3300 RIVERMONT AVE | LYNCHBURG | VA | 24503 | 32 |
| No | ICD Diagnosis Code | Description |
|---|---|---|
| 1 | M6282 | Rhabdomyolysis |
| 2 | I2510 | Atherosclerotic heart disease of native coronary artery without angina pectoris |
| 3 | E785 | Hyperlipidemia, unspecified |